The current and future treatment paradigm of ALK rearranged NSCLC

Jay Lee, MD, University of California, Los Angeles, CA, provides an overview the current state of ALK TKI-directed therapies in the early-stage non-small cell lung cancer (NSCLC), highlighting the need for further development in later generations of TKIs. Dr Lee comments on the safety profile and efficacy of second-generation ALK TKIs, including pathologic regression and radiographic response rates from Phase II clinical trials, as well as some studies with first-generation crizotinib. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.